Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/ritonavir plus emtricitabine/tenofovir vs lopinavir/ritonavir plus raltegravir in treatment-naive HIV-1 infection
2008-000881-22Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Virologic suppression at week 48. Started May 2008; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-000881-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000881-22.